title: The prevalence of pantoprozole associated thrombocytopenia in a community hospital.
abstract: OBJECTIVE
  Proton pump inhibitors (PPIs) are widely used in the treatment of gastritis, gastroesophageal reflux disease and peptic ulcer disease. Thrombocytopenia is not listed as one of the main side effects of PPI therapy. However, there have been documented cases of thrombocytopenia with the use of PPIs in the literature. Our objective was to determine whether exposure to PPIs leads to an increased incidence of thrombocytopenia in hospitalized patients.
  
  
  METHODS
  This retrospective cohort study examined the platelet counts of 468 hospitalized patients who were 18 - 80 years of age, were prescribed pantoprazole for a minimum of 3 days and were matched to 468 non-medicated controls. The primary outcome was defined as either a drop in the platelet count by >/= 50% relative to baseline, or a drop to < 150,000/ml. Exclusion criteria were baseline thrombocytopenia and hospitalization for < 3 days.
  
  
  RESULTS
  No difference was found in the occurrence of thrombocytopenia between the two groups (6.2%; 95% CI = 4.1 - 8.7%) in the study group versus (6.6%; 95% CI = 4.5 - 9.2%) in the control group (p = 0.90). Post-hoc analysis revealed a higher incidence of > 20% drop in platelet count in the study group compared with the controls (23%; 95% CI = 19 - 27% versus 11%; 95% CI = 8 - 14%, respectively; p < 0.001).
  
  
  CONCLUSIONS
  This study failed to demonstrate an increased incidence of thrombocytopenia for patients treated with pantoprazole. Our study adds support to the favorable safety profile of PPI therapy in hospitalized patients. Further investigation is needed to evaluate the effects of PPI use in the outpatient setting.
authors: Lenox Hill Hospital, Department of Hematology, 100 East 77th street, New York, NY 10021 +1 212 434 2000 ; +1 212 434 2446 ; cspaccavento@lenoxhill.net.
authors: Efrat
authors: E
authors: Dotan
authors: Randi
authors: R
authors: Katz
authors: Jason
authors: J
authors: Bratcher
authors: Carrie
authors: C
authors: Wasserman
authors: Michelene
authors: M
authors: Liebman
authors: Georgia
authors: G
authors: Panagopoulos
authors: Colette
authors: C
authors: Spaccavento
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000009:adverse effects*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D005260:Female; D006760:Hospitalization; D006764:Hospitals, Community; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077402:Pantoprazole; D015995:Prevalence; D012189:Retrospective Studies; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000453:epidemiology*
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000077402:Pantoprazole